Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Single-administration, Open-label Trial to Assess the Efficacy, Safety, PK, and PD of Dasiglucagon When Administered as a Rescue Therapy for Severe Hypoglycemia in Pediatric Patients Below 6 Years of Age With Type 1 Diabetes (T1D)

NCT05378672 is registered in ClinicalTrials.gov with Zealand Pharma as lead sponsor.

NCT NCT05378672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05378672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Single-administration, Open-label Trial to Assess the Efficacy, Safety, PK, and PD of Dasiglucagon When Administered as a Rescue Therapy for Severe Hypoglycemia in Pediatric Patients Below 6 Years of Age With Type 1 Diabetes (T1D)
Lead sponsor
Zealand Pharma
Phase
Phase 3
Overall status
Completed
Start date
May 9, 2023
Completion date
December 3, 2024
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hypoglycemia, type 1 diabetes